Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
This activity is supported by Regeneron Pharmaceuticals, Inc.
Overview
Release Date
September 15, 2024
Expiration Date
September 15, 2025
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by Regeneron Pharmaceuticals, Inc.
Activity Overview
In this educational program, a panel of retina experts engages in case-based discussions that provide insights into the use of newer anti-VEGF therapies that can provide reduced treatment burden for patients with neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR) and diabetic macular edema (DME), and retinal vein occlusion (RVO).
Target Audience
This educational activity is directed toward retinal specialists who treat patients with nAMD and DME. Ophthalmologists and other health care professionals interested in the treatment of nAMD and DME are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Implement evidence-based treatment algorithms for patients with nAMD in clinical practice
- Implement evidence-based treatment algorithms for patients with diabetic eye disease in clinical practice
- Implement evidence-based treatment algorithms for patients with RVO in clinical practice
Faculty
David M. Brown, MD, FACS
Clinical Professor of Ophthalmology
Baylor College of Medicine
Director of Research
Retina Consultants of Texas
Chair, Medical Leadership Board,
Retina Consultants of America
Houston, TX
Disclosures: Consultant: AAVantgarde Bio; AbbVie; Alexion Pharmaceuticals; Annexon; Apellis Pharmaceuticals; Bayer; Biogen MA; Boehringer Ingelheim; Celltrion; Chengdu Kanghong Pharmaceutical; Clearside Biomedical; Heidelberg Engineering; Impact Education; Kowa; Novartis Pharma AG; Ocular Therapeutix; Ocuphire Pharma; OPTOS PLC; Pontifax; Regeneron Pharmaceuticals; RetinAI Medical AG; Ray Therapeutics; Samsung Bioepis; Senju Pharmaceuticals; SIMR Biotech; Stealth BioTherapeutics; THEA; Topcon; Xequel Bio;
Grants: AffaMed Therapeutics (US); Alcon; Alexion Pharmaceuticals; Allergan; Amgen; Annexon; Apellis Pharmaceuticals; Astellas; Bayer; BIRC; Boehringer Ingelheim; Chengdu Kanghong Biotechnology; Clearside; Eyebiotech; EyePoint Pharmaceuticals; F. Hoffmann- La Roche Limited; Gemini Therapeutics; Genentech; Graybug Vision; Gyroscope Therapeutics; Heidelberg Engineering; i-Lumen Scientific; IONIS Pharmaceuticals; Jaeb-/DRCR AA; Jeff Heier, MD; Kodiak Sciences; LumiThera; MeiraGTx; Mylan; NEI/NIH; NGM Biopharmaceuticals; Novartis; Ocular Therapeutix; Ocuphire Pharma; OcuTerra Therapeutics; Opthea; OPTOS; Outlook Therapeutics; OXULAR; Pennsylvania State University; Regeneron Pharmaceuticals; RegenXBio; Rezolute; SamChunDang; Samsung; Sandoz Biopharmaceuticals; Santen; SciFluor Life Sciences; Senju Pharmaceutical; Shanghai Henlius Biotech; Stealth BioTherapeutics; Taiwan Liposome Company; Thrombogenics; Xbrane; Zeiss Meditec;
Other: OPTOS-Camera Software (used to de-warp images), Adverum, Clearside Biomedical, Ocuphire Pharma.
David A. Eichenbaum, MD
Director, Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Clearwater, FL
Disclosures: Grant/Research Support: 4DMT Molecular Therapeutics, Alexion, Allgenesis Biotherapeutics, Annexon, Aviceda Therapeutics, Bayer, EyePoint Pharmaceuticals, Gemini, Gyroscope Therapeutics, Ionis Pharmaceuticals, IVERIC bio, Janssen, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, ONL Therapeutics, Opthea, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Unity;
Consultant: Alimera Sciences, Allergan, Annexon, Apellis Pharmaceuticals, Bausch + Lomb, Coherus BioSciences, Crinetics Pharmaceuticals, EyePoint Pharmaceuticals, Genentech, IVERIC bio, Kodiak Sciences, Ocular Therapeutix, Opthea, Outlook Therapeutics, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, ReVive, Samsara;
Speakers Bureau: Allergan, Apellis Pharmaceuticals, Genentech, IVERIC bio, Regeneron Pharmaceuticals;
Shareholder: Boston Image Reading Center, Janssen, Network Eye, USRetina.
Hong-Uyen Hua, MD
Assistant Professor of Clinical Ophthalmology
Pediatric and Adult Retina Specialist
Bascom Palmer Eye Institute
University of Miami Health System
Miami, FL
Disclosures: Consultant: AbbVie, Alimera Sciences, Genentech.
Prethy Rao, MD, MPH, FACS
Co-Fellowship Director
Retina and Vitreous of Texas
Houston Methodist Hospital/Blanton Eye Institute
Houston, TX
Disclosures: Consultant: B&L, Regeneron, Vortex;
Advisory Board: Genentech, Iveric Bio, EyePoint;
Grant/Research Support: Dutch Ophthalmic Research Center, Regenxbio (research/clinical trial consultant)
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.